SCHEMBL2220758

SCHEMBL2220758

CCOC(=O)C#CBr

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18446 0.84 ALDH1A1 (0.53)
SCHEMBL23234042 0.80
SCHEMBL2948744 0.79 ALDH1A1 (0.48)
SCHEMBL125810 0.77
SCHEMBL16811766 0.77 ALDH1A1 (0.50)
SCHEMBL27767863 0.77
SCHEMBL733363 0.76
SCHEMBL2945943 0.75 GAA (0.46)
SCHEMBL28689574 0.75
SCHEMBL23212269 0.75

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12570612-B2 Substituted nitrogen heterocyclic compound and anesthetic effect thereof CHENGDU MFS PHARMA. CO., LTD. (CN) 2026-03-10 US disclosed
US-20230026724-A1 SUBSTITUTED NITROGEN HETEROCYCLIC COMPOUND AND ANESTHETIC EFFECT THEREOF CHENGDU MFS PHARMA. CO., LTD. (CN) 2023-01-26 US disclosed
CN-115197046-A Halogenation method of unsaturated hydrocarbon 华南理工大学 2022-10-18 CN disclosed
EP-4043440-A1 SUBSTITUTED NITROGEN HETEROCYCLIC COMPOUND AND ANESTHETIC EFFECT THEREOF CHENGDU MFS PHARMA. CO., LTD. (CN) 2022-08-17 EP disclosed
CN-114262301-A Small molecule antagonist targeting EP4 receptor and application thereof in osteoarthritis and cartilage defect treatment 华东师范大学 2022-04-01 CN disclosed
WO-2021068943-A1 SUBSTITUTED NITROGEN HETEROCYCLIC COMPOUND AND ANESTHETIC EFFECT THEREOF 成都麻沸散医药科技有限公司 2021-04-15 WO disclosed
WO-2020257487-A1 GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE BIOMARIN PHARMACEUTICAL INC. (US) 2020-12-24 WO disclosed
CN-108929281-A Triazole compound and synthesis method and application thereof 华东师范大学 2018-12-04 CN disclosed
US-9884847-B2 Indazole retinoic acid receptor-related orphan receptor modulators and uses thereof INNOV17 LLC (US) 2018-02-06 US disclosed
WO-2017184549-A1 PYRROLOPYRIDINE RETINOIC ACID RECEPTOR-RELATED ORPHAN RECEPTOR MODULATORS AND USES THEREOF INNOV17 LLC (US) 2017-10-26 WO disclosed
US-8481549-B2 Dual-acting thiophene, pyrrole, thiazole and furan antihypertensive agents THERAVANCE, INC. (US) 2013-07-09 US disclosed
WO-2011090929-A1 DUAL-ACTING THIOPHENE, PYRROLE, THIAZOLE AND FURAN ANTIHYPERTENSIVE AGENTS THERAVANCE, INC. (US) 2011-07-28 WO disclosed
WO-2011090929-A1 DUAL-ACTING THIOPHENE, PYRROLE, THIAZOLE AND FURAN ANTIHYPERTENSIVE AGENTS THERAVANCE, INC. (US) 2011-07-28 WO disclosed
US-20110178101-A1 DUAL-ACTING THIOPHENE, PYRROLE, THIAZOLE AND FURAN ANTIHYPERTENSIVE AGENTS THERAVANCE BIOPHARMA R&D IP, LLC 2011-07-21 US disclosed
US-20110178101-A1 DUAL-ACTING THIOPHENE, PYRROLE, THIAZOLE AND FURAN ANTIHYPERTENSIVE AGENTS THERAVANCE BIOPHARMA R&D IP, LLC 2011-07-21 US disclosed
CN-1044235-C Sulfonamide endothelin antagonists SQUIBB & SONS INC (US) 1999-07-21 CN disclosed
EP-0558258-B1 N-isoxazole-naphthylsulfonamide derivatives and their use as endothelin antagonists SQUIBB & SONS INC (US) 1997-05-07 EP disclosed
US-5378715-A Sulfonamide endothelin antagonists BRISTOL-MYERS SQUIBB CO. (US) 1995-01-03 US disclosed
CN-1079468-A Sulfonamide endothelin antagonists SQUIBB & SONS INC (US) 1993-12-15 CN disclosed
EP-0558258-A1 N-isoxazole-naphthylsulfonamide derivatives and their use as endothelin antagonists E.R. SQUIBB &amp; SONS, INC. (US) 1993-09-01 EP disclosed